Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Pierre–Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 11, pp. 888-900
Closed Access | Times Cited: 10

Showing 10 citing articles:

Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost
Marco Zampoli, Janine Verstraete, Cathy Baird, et al.
Journal of Cystic Fibrosis (2025)
Closed Access | Times Cited: 2
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access | Times Cited: 2
Cystic fibrosis year in review 2024
Amel Alameeri, Burcu Capraz, Francesca Lucca, et al.
Journal of Cystic Fibrosis (2025)
Closed Access | Times Cited: 1
Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium
Simon Y. Graeber, Olaf Sommerburg, Yin Yu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Expanding CFTR modulator access to benefit all patients who are waiting for a lung transplant
Ruairı́ Brugha, Kavita Dave, Vicky Gerovasili, et al.
The Lancet Respiratory Medicine (2025) Vol. 13, Iss. 2, pp. e10-e10
Closed Access
Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
Burkhard Tümmler, Sophia T. Pallenberg, Anna‐Maria Dittrich, et al.
Molecular and Cellular Pediatrics (2025) Vol. 12, Iss. 1
Open Access
Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis
Katherine Odem‐Davis, Jennifer L. Taylor‐Cousar
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 11, pp. 842-844
Closed Access
The day after. Rethinking the Cystic Fibrosis model of care and structure of the CF team in the era of triple combination therapy
Philippe Reix
Journal of Cystic Fibrosis (2024)
Closed Access
Until it's done for everyone: the role of CFTR modulator label expansion
Clemente J. Britto, Jennifer L. Taylor‐Cousar
European Respiratory Journal (2024) Vol. 64, Iss. 5, pp. 2401898-2401898
Closed Access
Treatment effects of elexacaftor/tezacaftor/ivacaftor on people with cystic fibrosis heterozygous for 3849+10kbC->T and a class I variant
Moshe Heching, Michal Shteinberg, Inbal Golan‐Tripto, et al.
Journal of Cystic Fibrosis (2024)
Closed Access
Page 1

Scroll to top